JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY) ›› 2018, Vol. 32 ›› Issue (3): 14-17.doi: 10.6040/j.issn.1673-3770.1.2017.054

Previous Articles     Next Articles

Endotype of chronic rhinosinusitis: from basic to clinical research

ZHANG Guimin, LIN Peng   

  1. Department of Otorhinolaryngology Head and Neck Surgery, Tianjin First Central Hospital, Tianjin 300192, China
  • Received:2017-11-29 Online:2018-05-20 Published:2018-05-20

Abstract: Chronic rhinosinusitis(CRS)is a complex disease that involves multiple factors and is characterized by chronic persistent inflammation of the nasal and sinus mucosa. Owing to the high heterogeneity and complicated pathological mechanism, polyps of different endotypes may exhibit the same phenotype. The present research on the endotype of chronic rhinosinusitis focuses on the cellular and molecular biology aspects of the disease onset. We expect to identify specific molecular markers, which can be used as target molecules for accurate individualized treatment.

Key words: Accurate treatment, Molecular biology, Rhinosinusitis, chronic

CLC Number: 

  • R765.4
[1] 周兵, 韩德民.鼻内镜外科基本技术的再认识与发展[J]. 中华耳鼻咽喉头颈外科杂志, 2011, 46(6):441-443.
[2] Bachert C, Holtappels G. Pathophysiology of chronic rhinosinusitis, pharmaceutical therapy options[J]. GMS Curr Top Otorhinolaryngol Head Neck Surg, 2015, 14:Doc09. DOI:10.3205/cto000124.
[3] Gevaert P, Lang-Loidolt D, Lackner A, et al. Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps[J]. J Allergy Clin Immunol, 2006, 118(5):1133-1141.
[4] Gevaert P, Van BN, Cattaert T, et al. Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis[J]. J Allergy Clin Immunol, 2011, 128(5):989-995.
[5] Gevaert P, Calus L, Zele T, et al. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma[J]. J Allergy Clin Immunol, 2013, 131(1):110-116.
[6] Lane AP, Truongtran QA, Schleimer RP.Altered expression of genes associated with innate immunity and inflammation in recalcitrant rhinosinusitis with polyps[J]. Am J Rhinol, 2006, 20(2):138-144.
[7] Adappa ND, Zhang Z, Palmer JN, et al. The bitter taste receptor T2R38 is an independent risk factor for chronic rhinosinusitis requiring sinus surgery[J]. Int Forum Allergy Rhinol, 2014, 4(1):3-7.
[8] Lee RJ, Cohen NA.The emerging role of the bitter taste receptor T2R38 in upper respiratory infection and chronic rhinosinusitis[J]. Am J Rhinol Allergy, 2013, 27(4):283-286.
[9] Nagarkar DR, Poposki JA, Tan BK, et al. Thymic stromal lymphopoietin activity is increased in nasal polyps of patients with chronic rhinosinusitis[J]. J Allergy Clin Immunol, 2013, 132(3):593-600.
[10] Baba S, Kondo K, Kanaya K, et al. Expression of IL-33 and its receptor ST2 in chronic rhinosinusitis with nasal polyps[J]. Laryngoscope, 2014, 124(4):E115-122.
[11] Lam M, Hull L, Mclachlan R, et al. Clinical severity and epithelial endotypes in chronic rhinosinusitis[J]. Int Forum Allergy Rhinol, 2013, 3(2):121-128.
[12] Lam M, Hull L, Imrie A, et al. Interleukin-25 and interleukin-33 as mediators of eosinophilic inflammation in chronic rhinosinusitis[J]. Am J Rhinol Allergy, 2015, 29(3):175-178.
[13] Yao T, Kojima Y, Koyanagi A, et al. Eotaxin-1, -2, and-3 immunoreactivity and protein concentration in the nasal polyps of eosinophilic chronic rhinosinusitis patients[J]. Laryngoscope, 2009, 119(6):1053-1059.
[14] Divekar R, Kita H.Recent advances in epithelium-derived cytokines(IL-33, IL-25, and thymic stromal lymphopoietin)and allergic inflammation[J]. Curr Opin Allergy Clin Immunol, 2015, 15(1):98-103.
[15] Lam M, Hull L, Mclachlan R, et al. Clinical severity and epithelial endotypes in chronic rhinosinusitis[J]. Int Forum Allergy Rhinol, 2013, 3(2):121-128.
[16] Shin HW, Kim DK, Park MH, et al. IL-25 as a novel therapeutic target in nasal polyps of patients with chronic rhinosinusitis[J]. J Allergy Clin Immunol, 2015, 135(6):1476-1485.
[17] Kato A, Favoreto S, Avila PC, et al. TLR3-and Th2 cytokine-dependent production of thymic stromal lymphopoietin in human airway epithelial cells[J]. J Immunol, 2007, 179(2):1080-1087.
[18] Lee HC, Ziegler SF. Inducible expression of the proallergic cytokine thymic stromal lymphopoietin in airway epithelial cells is controlled by NFkappaB[J]. Proc Natl Acad Sci U S A, 2007, 104(3):914-919.
[19] Boita M, Garzaro M, Raimondo L, et al. Eosinophilic inflammation of chronic rhinosinusitis with nasal polyps is related to OX40 ligand expression[J]. Innate Immun, 2015, 21(2):167-174.
[20] Liu T, Li TL, Zhao F, et al. Role of thymic stromal lymphopoietin in the pathogenesis of nasal polyposis[J]. Am J Med Sci, 2011, 341(1):40-47.
[21] Mjösberg JM, Trifari S, Crellin NK, et al. Human IL-25-and IL-33-responsive type 2 innate lymphoid cells are defined by expression of CRTH2 and CD161[J]. Nat Immunol, 2011, 12(11):1055-1062.
[22] Robinette ML, Colonna M.Immune modules shared by innate lymphoid cells and T cells[J]. J Allergy Clin Immunol, 2016, 138(5):1243-1251.
[23] Morita H, Moro K, Koyasu S. Innate lymphoid cells in allergic and nonallergic inflammation[J]. J Allergy Clin Immunol, 2016, 138(5):1253-1264.
[24] Bal SM, Bernink JH, Nagasawa M, et al. IL-1β, IL-4 and IL-12 control the fate of group 2 innate lymphoid cells in human airway inflammation in the lungs[J]. Nat Immunol, 2016, 17(6):636-645.
[25] Van Zele T, Claeys S, Gevaert P, et al. Differentiation of chronic sinus diseases by measurement of inflammatory mediators[J]. Allergy, 2006, 61(11):1280-1289.
[26] Zhang N, Van ZT, Pereznovo C, et al. Different types of T-effector cells orchestrate mucosal inflammation in chronic sinus disease[J]. J Allergy Clin Immunol, 2008, 122(5):961-968.
[27] Wang X, Zhang N, Bo M, et al. Diversity of TH cytokine profiles in patients with chronic rhinosinusitis: a multicenter study in Europe, Asia, and Oceania[J]. J Allergy Clin Immunol, 2016, 138(5):1344-1353.
[28] Tomassen P, Vandeplas G, Van Zele T, et al. Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers[J]. J Allergy Clin Immunol, 2016, 137(5):1449-1456.
[29] Kim JW, Hong SL, Kim Yk, et al. Histological and immunological features of non-eosinophilic nasal polyps[J]. Otolaryngol Head Neck Surg, 2007, 137(6):925-930.
[30] Ba L, Zhang N, Meng J, et al. The association between bacterial colonization and inflammatory pattern in Chinese chronic rhinosinusitis patients with nasal polyps[J]. Allergy, 2011, 66(10):1296-1303.
[31] Orlandi RR, Kingdom TT, Hwang PH. International consensus statement on allergy and rhinology: rhinosinusitis executive summary[J]. Int Forum Allergy Rhinol, 2016. DOI: 10.1002/alr.21694.
[32] Sommer DD, Rotenberg BW, Sowerby LJ, et al. A novel treatment adjunct for aspirin exacerbated respiratory disease:the low-salicylate diet:a multicenter randomized control crossover trial[J]. Int Forum Allergy Rhinol, 2016, 6(4):385-391.
[33] Cingi C, Muluk NB, Ipci K, et al. Antileukotrienes in upper airway inflammatory diseases[J]. Curr Allergy Asthma Rep, 2015, 15(11):64.
[34] Laidlaw TM, Kidder MS, Bhattacharyya N, et al. Cysteinyl leukotriene overproduction in aspirin-exacerbated respiratory disease is driven by platelet-adherent leukocytes[J]. Blood, 2012, 119(16):3790-3798.
[1] WU Jian, FAN Jingping, LIU Huanhai, LANG Juntian, LU Xiaoqing, XU Yaping. 3D technology for accurate treatment of transnasal endoscopic nasal skull base neoplasm resection and the functional reconstruction. [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2016, 30(6): 24-28.
Full text



No Suggested Reading articles found!